Establishment of assay method for p95HER2 protein that is a Resistance factor in anti-HER2 molecular-targeted therapy
Project/Area Number |
22890004
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Laboratory medicine
|
Research Institution | Hokkaido University |
Principal Investigator |
HATANAKA Yutaka 北海道大学, 北海道大学病院, 特任助教 (30589924)
|
Project Period (FY) |
2010 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥3,042,000 (Direct Cost: ¥2,340,000、Indirect Cost: ¥702,000)
Fiscal Year 2011: ¥1,456,000 (Direct Cost: ¥1,120,000、Indirect Cost: ¥336,000)
Fiscal Year 2010: ¥1,586,000 (Direct Cost: ¥1,220,000、Indirect Cost: ¥366,000)
|
Keywords | 分子標的治療 / 治療抵抗性 / コンパニオン診断 |
Research Abstract |
In this study, we developed a monoclonal antibody to p95HER2 that is a resistance factor in anti-HER2 therapy. N-terminal synthetic peptides of p95HER2(Met611-Cys623) was conjugated with KLH, and used as immunogens. From the obtained hybridomas, we selected clones specific to the synthetic peptide by ELISA screening and dot blotting. Antibodies generated from the clones were avaliable in formalin-fixed, paraffin-embedded cell block. These results suggest that the antibodies would be useful to establish biochemical and immunohistochemical assays for selecting patients who exhibit resistance to HER2 therapy.
|
Report
(3 results)
Research Products
(16 results)
-
-
[Journal Article] Bright-field dua l-color chromogenic in situ hybridi zation for diagnosing echinoderm mi crotubule-associated protein-like 4-anaplastic lymphoma kinase-positiv e lung adenocarcinomas2011
Author(s)
Yoshida A, Tsuta K, Nitta H, Hatana ka Y, Asamura H, Sekine I, Grogan T M, Fukayama M, Shibata T, Furuta K, Kohno T, Tsuda H.
-
Journal Title
J Thorac On col
Volume: 6
Pages: 1677-86
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy2010
Author(s)
Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hirakawa A, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y.
-
Journal Title
J Surg Oncol
Volume: 101
Pages: 222-7
Related Report
Peer Reviewed
-
[Journal Article] Disruption of the blood brain barrier by brain metastases of triple negative and basal-type breast cancer but not HER2/neu-positive breast cancer2010
Author(s)
Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Nakanishi Y, Miyakita Y, Narita Y, Shibui S, Fujiwara Y.
-
Journal Title
Cancer
Volume: 116
Pages: 302-8
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-